Status: Recruiting
Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug
Assessment of immunogenicity, reactogenicity and safety of GNG-DE in comparison with the reference drug
Participants needed: 240
Trial details
Phase: Phase 3Age: 3-55Biological sex: AllType: InterventionalSponsor: NPO PetrovaxUpdated: Dec 29, 2025Locations: 17
Eligibility criteria
Male and female subjects aged 3-55 years old inclusive at the time of screening... [+5]
Hypersensitivity to any component of the test/reference drug. [+22]